666

ENIMMUNE CORPORATI

No trades
See on Supercharts

6564 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Enimmune Corp. engages in the research, development of new drugs. Its products include EV71, Japanese encephalitis virus, EV71+CA16 bivalent, tetanus toxoid adsorbed, influenza, AH1N1, and pneumococcal vaccines. The company operates pharmaceutical outlets. Enimmune was founded on January 10, 2014 and is headquartered in Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

6564 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company